Crossmark

Re: Re: Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie’s disease

Published Online: 2019-08-16

Published Print: 2020-03

Authors

Tsambarlis, Peter

Levine, Laurence A.
License Information

Text and Data Mining valid from 2019-08-16

Version of Record valid from 2019-08-16
More Information

Article History

Received: 21 June 2019

Accepted: 24 June 2019

First Online: 16 August 2019

Compliance with ethical standards

:

: LAL is a speaker and consultant for Boston Scientific and Coloplast. PT declares that he has no conflicts of interest.

Document is current